Burrill & Co. LLC

Burrill & Co. LLC

Burrill & Co. LLC

Date Founded



1 Embarcadero Center,Suite 2700,San Francisco, CA 94111-3776

Type of Company



Private Equity & Venture Capital
Accounting & Financial Services
Investment Services & Portfolio Management

Company Description

Burrill & Co.'s venture capital activities focus exclusively on life science companies whose technologies and products are applicable across range of life science sub-sectors including: (1) human healthcare therapeutics and diagnostics/devices (2) health/wellness (3) agricultural biotechnology (4) biofuels and (5) industrial biotechnology, biomaterials and bioprocesses. In addition, to sector diversification, the firm also diversifies across investment stage. In general, most of their investments are in the start-up through mezzanine stage. Most of the firm's investments are made in series A and B rounds. They do invest in public entities. Burrill & Co. principally invests in the US and Europe. The firm's professionals usually serve on the board of directors of each portfolio company and, when necessary, assist with operational activities. Investments tend to average from $5 million to $15 million over the life of a company.Burrill & Co.'s private equity investments focus on investments in undervalued small-cap and mid-cap public companies and selected buy-outs and spin-outs from pharmaceutical, biotechnology and other life sciences entities. The firm seeks to acquire significant equity positions often through PIPEs and to optimize opportunities for future equity financing, acquisitions and divestitures.

Executives & Employees

Senior Managing Director, Burrill Securities

Vice Chairman

Chief Financial Officer & Chief Operating Officer

Chief Financial Officer

Venture Partner

Venture Partner

Managing Director, General Manager Europe/Managing Director, Digital Health

Venture Partner, Russia

Managing Editor

Managing Director

Paths to Burrill & Co. LLC
Potential Connections via
Relationship Science
Burrill & Co. LLC
Recent Transactions
Details Hidden

Chromatin, Inc., Burrill & Co. LLC purchase Kirkland Seed, Inc.

Details Hidden

Chromatin, Inc., Burrill & Co. LLC purchase Majestic Semillas S. De R.L. De C.V.

Details Hidden

LifeWatch AG purchases AliveCor, Inc. from Khosla Ventures LLC, Qualcomm Ventures, Chisholm Private Capital Partners LC, Burrill & Co. LLC

Transaction Clients
Investment Advisor

Advised on Nuo Therapeutics, Inc. purchases Aldagen, Inc. from Harbert Venture Partners LLC

Investment Advisor

Advised on Evotec AG purchases Compound Focus, Inc. from Galapagos NV

Investment Advisor

Advised on Everi Games Holding, Inc. purchases PokerTek, Inc.

Transaction Advisors
Escrow Agent

Advised onTargacept, Inc. purchases Catalyst Bioscience, Inc. (Inactive) from Sofinnova Ventures, Inc., Burrill & Co. LLC, Johnson & Johnson Innovation JJDC, Inc., HealthCare Ventures LLC, Rosetta Capital Ltd., Morgenthaler Management Corp.

Legal Advisor

Advised onBurrill & Co. LLC purchases CareDx, Inc.

Details Hidden

Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium.

Details Hidden

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. In addition, Neos manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded on June 15, 2009 and is headquartered in Grand Prairie, TX.

Details Hidden

Nora Therapeutics, Inc. develops therapeutics to address clinical unmet needs in reproductive medicine. Its's lead product NT100, seeks to improve pregnancy outcomes in women undergoing in vitro fertilization or who have suffered recurrent spontaneous miscarriages. The company was founded by Darryl L. Carter and Chris B. McClain in 2007 and is headquartered in Palo Alto, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Burrill & Co. LLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Burrill & Co. LLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Burrill & Co. LLC.